Pay more attention to Ethynyl estradiol
Ethynyl estradiol is a Off-White to Light-Yellow Crystalline Powder, it may be used as a metabolite of 17a-Ethynylestradiol. The Molecular Formula is C20H24O2, Molecular Weight is 296.40336. Keep Ethynyl estradiol in a cool, dry, dark location in a tightly sealed container or cylinder. Keep it away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. The CAS Registry Number is 57-63-6.
The first orally active semisynthetic steroidal estrogen, Ethynyl estradiol was synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering AG in Berlin.It was approved by the FDA in the U.S. on June 25, 1943 and marketed by Schering as Estinyl.The FDA withdrew approval of Estinyl effective June 4, 2004 at the request of Schering, who had discontinued marketing Estinyl.
Ethynyl estradiol(CAS NO: 57-63-6) is a hormone usually produced by the female ovaries and is crucial for normal female reproductive functioning. Estradiol is natural occurring form of estrogen. It helps the female reproductive organs to mature as well as helps the uterine wall prepare for the implantation of a fertilized egg.
But what side effects you know about Ethynyl estradiol? The most common side effects may include reducing cardiovascular risk, Gastrointestinal side effects, Endocrine side effects, Dermatologic side effects.
The effects of estrogen therapy in reducing cardiovascular risk are thought to be related to beneficial alterations in lipid profiles in treated women.Cardiovascular side effects have included studies suggesting that unopposed estrogen therapy decreased the risk of coronary heart disease by as much as 35%. Combination therapy with a progestin may have also decreased coronary risk. However, the extent of risk reduction with combination therapy has not been determined.
Gastrointestinal side effects have included frequent reports of nausea and vomiting. Some studies have demonstrated a 2 to 4 fold increase in gallbladder disease in postmenopausal women taking estrogen therapy.
Endocrine side effects have included increased levels of thyroxin-binding globulin, leading to an increase in total thyroid serum levels and a decrease in resin uptake of T3. Free thyroid hormone levels remain unchanged. Decreased fasting plasma glucose levels have been reported.
Dermatologic side effects have included chloasma or melasma. Resolution has not occurred in all cases following discontinuation of estrogen therapy. Scalp hair loss, hirsutism, erythema nodosum, and hemorrhagic eruptions have occurred.
If you need take Ethynyl estradiol, you should pay more attention to it. Learning more health information, properties or suppliers about Ethynyl estradiol, you can access Guidechem. Guidechem chemical B2B network provides information on china and global chemical market quotation and relative chemical Information.